Adrafiniili

Adrafinil (also known as Olmifon) is a prodrug for modafinil - a wakefulness-promoting agent (eugeroic) with nootropic effects. Adrafinil is metabolized in the liver to produce modafinil. Both are stimulants with no amphetamine-like effects. Safety information on adrafinil is lacking because modafinil is often used instead, for treatment of narcolepsy and excessive daytime sleepiness. Long-term supplementation of adrafinil is not advised, since adrafinil is metabolized into modafinil in the liver, and may stress the liver through elevated liver enzymes with prolonged use.

Also known as: Olmifon, Crl 40028

Classification

Psychoactive: Nootropic
Psychoactive: Stimulant
Tag: Benzhydryl
Tag: Diphenylmethylsulfinylacetamide
Tag: Eugeroic
Tag: Habit-Forming
Tag: Research-Chemical

Effects

Stimulation
Headache
Diarrhea
Increased Heart Rate
Nausea
Body Odor Alteration
Wakefulness
Focus Enhancement
Thought Acceleration
Memory Enhancement
Motivation Enhancement
Anxiety
Dehydration
Photophobia
Appetite Suppression
Increased Music Appreciation
Light Sensitivity
Increased Libido

Routes of Administration

Oral

Dosage

Heavy: 600 mg
Light: 100 – 250 mg
Common: 250 – 400 mg
Strong: 400 – 600 mg
Threshold: 100-150 mg

Duration

Onset: 0.75-2 h
Comeup: 0.75-1 h
Peak: 4.5-6 h
Offset: 1-3 h
After Effects: 2-6 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu